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A Novel Role for Neutrophils in Psoriasis?
Keratinocytes are highly sensitive to the proliferative, pro-
survival, and pro-migratory effects of multiple epidermal
growth factor receptor (EGFR) ligands, including EGF, trans-
forming growth factor-a (TGF-a), heparin-binding EGF-like
growth factor (HB-EGF), amphiregulin (AR), and epiregulin.
Interestingly, epidermal keratinocytes produce little or no
EGF, whereas several of the other growth factors are pro-
duced in substantial quantities. All of these ligands are ex-
pressed as transmembrane precursors, which must be
cleaved in order to interact with EGFR and elicit a prolifer-
ative response. In their article on p 338 of this issue, Meyer-
Hoffert, Wingertszahn, and Wiedow have demonstrated that
human leukocyte elastase (HLE) has the ability to stimulate
proliferation-cultured human keratinocytes via cleavage of
TGF-a. They demonstrate that the process is independent of
protease-activated receptors, but dependent upon the tyro-
sine kinase activity of the EGFR. They also showed that HLE
treatment transiently elevates intracellular calcium levels in
an EGFR-dependent fashion; however, proliferation was not
directly linked to proliferation in this study.
Although cleavage of HB-EGF and AR by metal-
loproteinases has previously been implicated in G-protein
coupled receptor (GPCR)-mediated activation of epithelial
tumor cells, little or no work has been focused on the po-
tential for ErbB ligand cleavage in normal epithelial cells
subjected to an inflammatory cell environment. The present
findings are of additional interest because elastase is a se-
rine protease, rather than a metalloproteinase, and because
they provide a novel mechanism by which the presence of
neutrophils in the upper layers of psoriatic epidermis might
contribute to epidermal hyperplasia in psoriasis. TGF-a is
highly expressed in the suprabasal layers of the epidermis,
where neutrophils tend to collect in psoriasis lesions. Thus,
however, so far no one has directly demonstrated increased
activation of the EGFR in psoriatic lesions, and it is certainly
possible that the signaling pathways that regulate keratin-
ocyte proliferation in culture (i.e., EGFR and extracellular
regulated kinase (ERK)) are different than those that may
predominate in vivo (i.e., NF-kB). Although the apparent lack
of apparent EGFR activation in psoriasis is puzzling, recent
studies by our laboratory and others have shown that only
low levels of keratinocyte EGFR activation are necessary for
full activation of ERK. Moreover, others have demonstrated
increased ERK phosphorylation and GTP loading of Ras (a
major link between EGFR and ERK activation) in psoriasis
lesions. Thus, although important questions remain unan-
swered, it remains reasonable to suspect that proteolytic
release of one or more EGFR ligands may prove to be the
‘‘missing link’’ between immune/inflammatory cell infiltration
and epidermal hyperplasia in psoriasis.
Neutrophilic infiltration of the epidermis is a relatively late
event in the development of psoriasis lesions, appearing
only after the appearance of dermal perivascular lymph-
ocytes and histiocytes, lymphocytic infiltration of the epi-
dermis, and the development of epidermal hyperplasia.
Thus, even if EGFR signaling is important for psoriatic ep-
idermal hyperplasia in vivo, it is hard to argue that elastase-
mediated cleavage of TGF-a would be the initial event
leading to epidermal hyperplasia. It could, however, play a
very important role in the spreading of psoriatic lesions, as
previous studies of patients with actively spreading plaques
were found to express greatly elevated levels of HLE. In
contrast, HLE levels were in the normal range in guttate
psoriasis lesions. This finding does not rule out a role for
autocrine ErbB stimulation at earlier stages of lesion devel-
opment, as AR, HB-EGF, and epiregulin are also overex-
pressed in psoriasis lesions. Each of these ligands could be
cleaved by different mechanisms, with different relation-
ships to the inflammatory infiltrate and/or to keratinocyte
signaling. Indeed, transgenic mice expressing AR in kera-
tinocytes have been found to develop inflammatory and
hyperplastic skin lesions resembling human psoriasis as
well as an inflammatory arthritis.
To date, there are no successful reports of psoriasis
treatment by antibodies or receptor tyrosine kinase inhib-
itors specific for EGFR. Whether this reflects unpublished
negative results or simply a paucity of clinical trials is un-
clear. The finding that only minimal EGFR activation is nec-
essary for full activation of ERK in cultured keratinocytes
suggests that therapeutically attainable levels of EGFR
blockade may be inadequate to shut down relevant down-
stream responses. Alternatively, EGFR signaling may prove
to be irrelevant to psoriatic epidermal hyperplasia in vivo.
Only time will tell.
Vectoring in on Melanoma
Melanoma continues to taunt us with its spontaneous re-
gressions, and yet we are not yet able to harness the power
of the immune system to cause this joyous event at will.
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Evidence from animal models and human clinical trials
strongly suggests that these remissions are due to immu-
nologic attack against the tumor. The ability to optimize
these immunological responses is therefore a key to im-
proved melanoma survival. Increasingly, we appreciate that
adaptive immune responses depend upon the quality of the
antecedent innate immune response. It is quite remarkable
that CpG oligonucleotides, which are much more common
in pathogen genomes than in the human genome, serve to
enhance the innate immune response by interacting with
the toll-like-receptor 9 on antigen-presenting cells, thereby
serving to boost the acquired immune response. The use of
such oligonucleotides is not new; however, previously, they
have usually been injected separately from the expres-
sion vector encoding the antigen. On p 371 of this issue,
Schneeberger, Wagner, and colleagues demonstrate that by
incorporating CpG oligonucleotides into the plasmid vector
used to express melanoma antigens, they can boost an
antigen-specific, cell-mediated response against melanoma
cells in a mouse model of cancer vaccination. This mane-
uver should ensure an optimal adjuvant effect of CpG DNA,
because these sequences are forced to be present in the
same cell that expresses the melanoma antigen.
It is important to recognize that this model has been
chosen precisely because this combination of melanoma
cells and host strain are known to be immunogenic. Unfor-
tunately, many human melanomas can outwit the immune
response by downregulating the HLA antigens required to
present antigen, and probably by other mechanisms as
well. Nevertheless, the results presented here are quite ro-
bust and encouraging that similar strategies will be of ben-
efit in human melanoma, especially when combined with
the ability to inject DNA capable of producing an optimal
cytokine brew for encouraging expression of MHC antigens
and otherwise encouraging the anti-tumor response.
Warts and Skin Cancer: Only Skin Deep?
Certain subtypes of human papillomavirus (HPV) (notably
HPV-16) have clearly been shown to have carcinogenic
properties in cervical neoplasia, and HPV sequences have
been reported in a high percentage of premalignant and ma-
lignant skin tumors. The association is particularly strong in
renal transplant patients, suggesting that the impaired im-
mune system of the transplant patient might be unable to
prevent HPV infection, allowing the virus to gain a foothold in
the skin. But the HPV types reported in these cancers have
been of many different types, and high levels of viral DNA
positivity have been reported in normal appearing skin of the
same patients. On p 388 of this issue, Forslund, Dillner, and
colleagues utilize PCR and DNA sequencing to compare the
prevalence, amount, and type of HPV DNA sequences found
on the exterior surface of various benign and malignant skin
tumors (seborrheic keratosis, actinic keratosis, squamous
cell carcinoma, and basal cell carcinoma) to those found in
the underlying tumor. To accomplish this, skin lesions were
tape-stripped prior to biopsy, and the viral DNA amplified
from the tape-strippings and punch biopsy of the lesion after
tape-stripping were compared with those obtained from
swabs taken from normal-appearing perilesional skin, fore-
head skin, and buttocks skin. Interestingly, they found that
the surface of lesional skin was far more likely to harbor HPV
DNA sequences than the underlying lesion (69% vs 12%,
po0.001), with similar findings for all lesion types examined.
Moreover, the prevalence and approximate amount of HPV
DNA that could be amplified from the tape-strippings was
very similar to that found in swabs from normal-appearing
skin, independent of lesion type or body site. Also, HPV DNA
sequences were much more abundant in tape-strippings and
skin swabs than in the underlying tumors.
These findings might be explained by viral DNA amplifi-
cation in the upper epidermal layers in the context of virus
production (indeed, intact virions were identified in a swab of
normal skin). But in approximately half of the cases in which
comparison was possible, the HPV types identified in the
biopsy of the underlying lesion after tape-stripping were dif-
ferent than those identified in the overlying tape-strippings.
This finding is not consistent with viral replication, and sug-
gests that the surface of our skin may be a reservoir for HPV
virions. These may have replicated elsewhere on our own
skin or hair, or may be drawn from the skin of others. This
very high prevalence of virus carriage without apparent in-
fection is a testament to the power of the stratum corneum
(along with other innate and acquired immune mechanisms)
to ward off HPV infection and to the power of PCR.
These results raise an important note of caution in
attempting to forge a causal link between HPV and skin
cancer. They, however, also provide a way to focus future
efforts to establish HPV causality in skin cancer on the rel-
atively small number of tumors that continue to carry HPV
after surface-stripping.
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